( th consecutive year Science magazine n...)First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes,Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes
th consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.
AstraZeneca Forward-Looking Statement
The statements herein include forward-looking statements. By their nature, forward-looking statements and forecasts involve risk and uncertainty. For a discussion of those risks and uncertainties please see the company's Annual Report/Form 20-F for 2006.
For more information about Bristol-Myers Squibb, please visit: www.bms.com.
For more information about AstraZeneca, please visit: www.astrazeneca-us.com.
CONTACT: Media, David M. Rosen of Bristol-Myers Squibb +1-609-252-5675 or(pager) +1-866-308-4484, , or David Albaugh ofAstraZeneca, +1-302-886-7098 or (cell) +1-609-304-3445,; Investors, John Elicker of Bristol-MyersSquibb, +1-212-546-3775, , or Mina Blair ofAstraZeneca, +44-20-7304-5084, david.m.rosen@bms.com david.albaugh@astrazeneca.com john.elicker@bms.com mina.blair@astrazeneca.com
Web site: http://www.bms.com/http://www.astrazeneca-us.com//
Ticker Symbol: (NYSE:BMY),(NYSE:AZN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>
Related medicine technology :
1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
9. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
Post Your Comments:
(Date:12/2/2008)...ire/ -- Horizon Therapeutics, Inc., a,privately h...t two pivotal,Phase 3 trials evaluating its lead ...ll primary endpoints. HZT-501, a novel, proprietar...ofen and famotidine, demonstrated a,statistically...roidal,anti-inflammatory drug (NSAID)-induced upp...
(Date:12/1/2008)...c. 2 A study has found ...chnique for imaging the breast, is not affected by...s, two factors that limit the effectiveness of sta...ults will be presented today at the annual meeting...A). , , "The ability of PEM to detect canc...
(Date:12/1/2008).../ -- S*BIO Pte Ltd today announced the initiation ...and orally-active JAK2 inhibitor, in leading medic...idiopathic myelofibrosis (CIMF). , , The t...bility of SB1518 in patients with CIMF and is expe... of the study will assess the safety profile and e...
(Date:12/1/2008)...1 gene is a two-way switch that, if turned off, ca...d so that they lose their identity and become more...Tenn., Dec. 1 Scientis...iscovered that a certain differentiated cell type ...s the constant expression of a gene called Prox1 ...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 1Global Med Technologies 28R 29 Inc to Announce Third Quarter Results On October 30th Conference Call to Follow Release 3786 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 1SI International Awarded 244 Million Army HRsolutions Task Order 3781 2SI International Awarded 244 Million Army HRsolutions Task Order 3781 3Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 1Compendia Bioscience Announces the Release and Availability of Oncomine 28TM 29 Research Premium Edition 1289 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 1CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 2CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 3CardioDynamics Ranked in Deloittes Technology Fast 50 Program for San Diego 1284 4[0] Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints[1] New Mammography Technology Effective in Detecting Breast Cancer[0] S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis[0] Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
...SINESS WIRE)--Apr 30, 2007 - CollaGenex,Pharmaceut...ew,report in the May 2007 issue of the Journal of ... randomized phase III clinical trials,demonstrate...e,doxycycline (Oracea(R), 40-mg doxycycline, USP c... has concluded these studies,establish the first i...
...cal Use Approval and Insurance Coverage Varies,Gre...R, N.Y. - April 30, 2007-- Most U.S. adults suppor...edures that can,impact people,s quality of life, i...ization, drugs to treat erectile,dysfunction and i...majorities also believe these types of treatments ...
Other Medicine Technology:Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4(Date:12/2/2008)... 2 MedPro Imaging, a premier provi...ounced the appointment of three,new ultrasound sa...ressive,expansion. The company also announced th...ties due to substantial growth throughout 2008. K...esident of Sales and Marketing in,February of thi...
(Date:12/2/2008)...ford researchers has developed a prototype blood s...ream in early stages of the disease, potentially a...roved chances of survival. , The system based on...iated proteins in a blood serum sample in less tha...existing commercial devices. In fact, the device, ...
(Date:12/2/2008)...ewswire/ -- MedCommons announces integration of it...rchive Solution for Healthcare,Organizations. The...,Organizations provides a modular DICOM-compliant ...s patient information, including medical images fr...ent-centric archive. The,integration with the Med...
(Date:12/2/2008)...with FDA in Early to Mid-2009 , , WARREN, N...ers of PharmFilm(R) technology and a drug delivery...maceutical products, and Strativa Pharmaceuticals,...utical Companies, Inc. (NYSE: PRX ), today annou...quivalence studies for a thin film formulation of ...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Stanford blood scanner detects even faint indicators of cancer 2Health News:Stanford blood scanner detects even faint indicators of cancer 3Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 2Health News:MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations 3Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3[0] MedPro Imaging Continues Aggressive U.S. Expansion[0] Stanford blood scanner detects even faint indicators of cancer[0] MedCommons HealthURL, a New Unified Clinical Viewer Appliance, Is Integrated with EMC Open Systems Archive Solution for Healthcare Organizations[0] MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
...uses genetic damage// in the developing fetus, say...ing during pregnancy causes genetic damage in the ...ephen G. Grant, Ph.D., associate professor of envi...health in the University of Pittsburgh Graduate Sc...
... by illnesses due to exposure to //pesticides have... to 2002, reports a research in the recent issue o...ronment is a health risk facing children and schoo...n the article states. Pesticides continue to be us...
...on (IMA) has today warned its members// all over t... dealing with patients who suffer from bullet, kni...oist violence taking place in the neighboring coun...affarpur district was arrested in May for treating...
...be used successfully to treat heart attacks//. Res...edicine had showed that it is possible to treat th...wo months, stem cells harvested from another pig?s...mal?s damaged heart restored heart function and re...
Other Medicine News:Health News:Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students 2Health News:Stem Cell Therapy For Treating Heart Attacks 2Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches.
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches.
Straight shafts with 7 mm tying platform. Flat serrated handle with dull titanium finish. Overall length 4.5 inches.
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches.
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |